VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the stock.

Separately, Benchmark reissued a “hold” rating on shares of VolitionRx in a research report on Friday, August 16th.

VolitionRx Price Performance

Shares of NYSE VNRX opened at $0.72 on Tuesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The company’s 50-day moving average is $0.65 and its 200 day moving average is $0.72. The stock has a market capitalization of $59.29 million, a P/E ratio of -1.55 and a beta of 1.12.

VolitionRx (NYSE:VNRX) last announced its earnings results on Wednesday, August 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01. The firm had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.34 million. Research analysts anticipate that VolitionRx will post -0.31 earnings per share for the current year.

Insider Transactions at VolitionRx

In other news, Director Guy Archibald Innes bought 150,000 shares of the firm’s stock in a transaction on Tuesday, August 20th. The stock was acquired at an average cost of $0.67 per share, with a total value of $100,500.00. Following the completion of the acquisition, the director now owns 406,683 shares of the company’s stock, valued at $272,477.61. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.80% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.